Continued access to vamorolone for boys with Duchenne muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This program gives boys with Duchenne muscular dystrophy who have already taken part in a vamorolone study continued access to the medicine. It aims to let them keep using vamorolone while extra information is gathered.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have already taken part in a vamorolone study and finished all required check-ins.
- Must not have had a serious or severe side effect from vamorolone that the doctor linked to the medicine.
- Must be willing to follow the study medicine plan and go to regular doctor visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
This study watches boys with Duchenne muscular dystrophy who are already taking Agamree (vamorolone) to see how safe it is over a long period. It helps doctors understand the medicine's effects over time.
This trial tests an experimental drug called givinostat in boys ages 2 to under 6 years with Duchenne muscular dystrophy (DMD). The study looks at how the drug works in the body and if it is safe, with the goal of finding new treatment options for young children.
This study tests whether a daily nutritional supplement called VM100 can improve quality of life for people with Duchenne muscular dystrophy. If you are 8 or older and your medications have been stable for at least 3 months, you may be able to participate.
This Phase 3 trial tests givinostat to see if it can improve safety and functional outcomes in boys with Duchenne muscular dystrophy who cannot walk. You might be a candidate if you meet age, genetic diagnosis, wheelchair-level mobility, and specific arm-strength/respiratory/heart criteria.
This study is checking how safe and effective ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, is when used in everyday clinics. It will help doctors understand more about the treatment's real-world effects and provide care for those who receive it.
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.